In a win for three generic drugmakers, a federal appeals court on Wednesday held that Novartis’ patent on the blockbuster multiple sclerosis drug Gilenya was invalid.
A unanimous panel of the U.S. Circuit Court of Appeals for the Federal Circuit affirmed a 2015 ruling by the U.S. Patent Trial and Appeal Board (PTAB), which agreed with generic drugmakers Torrent Pharmaceuticals, Apotex and Mylan Pharmaceuticals that the Gilenya patent was obvious based on a combination of prior innovations.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2opFJFV
